BIND Therapeutics Awarded the RUSNANOPRIZE 2013 for Innovative Development of Nanomedicine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today that BIND has been awarded the RUSNANOPRIZE 2013 for Innovative Development by the International Prize Award Committee. This award recognizes BIND for its translation of state-of-the-art nanoparticle technology into clinical-stage development. The award ceremony was held at the Moscow International Forum for Open Innovation in Moscow on November 1, 2013.

Help employers find you! Check out all the jobs and post your resume.